Systemic Therapy for Chondrosarcoma

Area of Science:

• Oncology
• Skeletal System Neoplasms
• Pharmacology

Background:

• Chondrosarcoma (CS) lacks standardized treatment protocols, particularly for advanced, unresectable cases.
• Treatment decisions often rely on histologic subtype and the presence of targetable mutations, such as IDH1.
• Conventional chemotherapy shows limited efficacy in conventional CS, necessitating exploration of alternative therapeutic strategies.

Purpose of the Study:

• To provide an overview of current and emerging treatment strategies for advanced, surgically unresectable chondrosarcoma.
• To highlight the importance of clinical trial participation for patients with limited therapeutic options.
• To discuss targeted therapies and their potential roles in managing different chondrosarcoma subtypes.

Main Methods:

• Review of existing literature and treatment guidelines for chondrosarcoma.
• Discussion of therapeutic agents based on chondrosarcoma subtype and molecular characteristics (e.g., IDH1 mutations).
• Consideration of treatment sequencing and off-label drug use in advanced disease.

Main Results:

• Conventional CS may benefit from antiangiogenic therapy (e.g., pazopanib) and IDH1 inhibitors (e.g., ivosidenib) if mutations are present.
• mTOR inhibitors and tyrosine kinase inhibitors are potential salvage options, but sequencing data is lacking.
• Dedifferentiated and mesenchymal CS subtypes have limited evidence for conventional chemotherapy, immunotherapy, or Ewing sarcoma-like regimens, with questionable efficacy in small studies.

Conclusions:

• Active enrollment in clinical trials is strongly recommended for advanced chondrosarcoma patients.
• Personalized treatment approaches considering histologic subtype and targetable mutations are essential.
• Further research is needed to establish clear treatment guidelines and optimize sequencing of therapies for refractory chondrosarcoma.